RxDoctor Payments Data

Christine Diblasi

Women's Health · Bel Air, MDNPI 1942979133

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 10 manufacturers, the largest accounting for just 17.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $294 and has fallen 93.0% since, to $21 in 2024. That places this record below the midpoint for women's health clinicians in MD, where the typical reported total is $327.

$334in general payments, 2019–2025

Across 17 payments — averaging $19.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$59
  • Mylan Pharmaceuticals Inc.$50
  • Coopersurgical, Inc.$47
  • Mayne Pharma Commercial LLC$46
  • Evofem Biosciences, Inc.$34
  • Daiichi Sankyo Inc.$29
  • plus $69 from 4 others

What the payments were for

  • Food & beverage$334100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$334 in reported general payments places this provider in the 50th percentile of 95 women's health providers in Maryland.

See all women's health providers in Maryland

Medicare billing

Part B allowed, 2024
$5,967
Medicare patients
77
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol26$2,174

Paid to pharmacies, not to this prescriber.

Other women's health in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →